Dimethyl fumarate - Biogen

Drug Profile

Dimethyl fumarate - Biogen

Alternative Names: BG-00012; BG-12; BG-12 oral fumarate; Delayed-release dimethyl fumarate; Delayed-release DMF; FAG-201; Gastro-resistant dimethyl fumarate; Gastro-resistant DMF; Panaclar; Tecfidera

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Biogen Idec
  • Class Anti-inflammatories; Antipsoriatics; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase I Pulmonary arterial hypertension
  • No development reported Rheumatoid arthritis
  • Discontinued Psoriasis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Multiple-sclerosis(In volunteers) in Hong Kong (PO, Controlled release)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Multiple-sclerosis(In volunteers) in United Kingdom (PO, Tablet)
  • 25 Oct 2017 Pooled integrated efficacy data from the phase III DEFINE, CONFIRM, and ENDORSE studies presented at 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top